Clinical Profile and Survival Outcome of Endometrial Cancer with p53 Mutation

被引:0
作者
Anila Tresa
Suchetha Sambasivan
P. Rema
Dhanya Dinesh
J. Sivaranjith
Sindhu P. Nair
Aleyamma Mathew
J. V. Ammu
Aswin Kumar
机构
[1] Regional Cancer Centre,Division of Gynecological Oncology
[2] Regional Cancer Centre,Division of Surgical Oncology
[3] Regional Cancer Centre,Department of Pathology
[4] Regional Cancer Centre,Division of Cancer Epidemiology & Biostatistics
[5] Regional Cancer Centre,Department of Radiation Oncology
来源
Indian Journal of Surgical Oncology | 2022年 / 13卷
关键词
Endometrial cancer; Survival; p53 mutation;
D O I
暂无
中图分类号
学科分类号
摘要
Clinicopathologic classification of endometrial cancer imperfectly reflects the tumor biology. Pathologic categorization — especially in high-grade tumors — results in an imprecise estimation of the risk of disease, recurrence, and death. Molecular subtyping is emerging as the standard of care in diagnosis and treatment of endometrial cancers. Molecular markers are important prognostic factors in tumor dissemination and early recurrence of endometrial cancers. TP53 mutation is an important prognostic factor for both serous and endometrioid cancers. The study aims to compare the clinical profile and overall survival of endometrial cancers with and without p53 mutation. Sixty-three patients who underwent surgical staging for carcinoma endometrium were included in the study.TP53 mutation status was determined based on p53 expression by immunohistochemistry (IHC) as a p53 wild or p53 mutant type. Data were analyzed for the clinical profile, p53 mutation status on IHC, histological pattern, tumor grade, stage of the disease, lymph node spread, recurrence pattern, treatment received, 2-year disease-free survival, and overall survival. Recurrence was noted in 12.7% patients after 2-year follow-up, of which 75% patients had p53 mutation. Significant association was seen between p53 expression and high-grade tumors, stage, cervical involvement, and adnexal involvement. The 2-year overall survival of the p53 wild type was 97.2% and the p53 mutant type was 91.7%. The 2-year disease-free survival for the p53 wild type was 94.3% and the disease-free survival of the p53 mutant variety was 83.5%. The 2-year disease-free survival for endometrioid carcinoma with p53 wild type was 100% and p53 mutant variety was 86.2% (p value 0.033). About 15.9% (10) patients were reassigned to the high-risk group needing chemotherapy and radiation according to the ESGO ESTRO 2021 consensus classification, due to their p53 mutation status. IHC to assess somatic p53 mutation may be done in endometrial biopsies irrespective of their histology. This may help to identify that the aggressive tumors thereby help in tailoring surgery, planning adjuvant treatment, and follow-up.
引用
收藏
页码:580 / 586
页数:6
相关论文
共 50 条
  • [41] Spectrum of p53 Tumor Suppressor Gene Mutations and Breast Cancer Survival
    Hong Lai
    Fangchao Ma
    Edward Trapido
    Lou Meng
    Shenghan Lai
    Breast Cancer Research and Treatment, 2004, 83 : 57 - 66
  • [42] Direct sequencing of the p53 gene shows absence of mutations in endometrioid endometrial adenocarcinomas expressing p53 protein
    Stewart, RL
    Royds, JA
    Burton, JL
    Heatley, MK
    Wells, M
    HISTOPATHOLOGY, 1998, 33 (05) : 440 - 445
  • [43] Significance of p53 expression in background endometrium in endometrial carcinoma
    Thuy Thi Nguyen
    Toru Hachisuga
    Rie Urabe
    Tomoko Kurita
    Seiji Kagami
    Toshinori Kawagoe
    Shohei Shimajiri
    Kazuki Nabeshima
    Virchows Archiv, 2015, 466 : 695 - 702
  • [44] Significance of p53 expression in background endometrium in endometrial carcinoma
    Thuy Thi Nguyen
    Hachisuga, Toru
    Urabe, Rie
    Kurita, Tomoko
    Kagami, Seiji
    Kawagoe, Toshinori
    Shimajiri, Shohei
    Nabeshima, Kazuki
    VIRCHOWS ARCHIV, 2015, 466 (06) : 695 - 702
  • [45] Angiogenesis, p53, and bcl-2 expression as prognostic indicators in endometrial cancer: Comparison with traditional clinicopathologic variables
    Erdem, O
    Erdem, M
    Dursun, A
    Akyol, G
    Erdem, A
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2003, 22 (03) : 254 - 260
  • [46] P53 overexpression in advanced-stage endometrial adenocarcinoma
    Kohler, MF
    Carney, P
    Dodge, R
    Soper, JT
    ClarkePearson, DL
    Marks, JR
    Berchuck, A
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1996, 175 (05) : 1246 - 1252
  • [47] Patterns and Biologic Features of p53 Mutation Types in Korean Breast Cancer Patients
    Kim, Hyung Won
    Lee, Hak Min
    Hwang, Seung Hyun
    Alm, Sung Gwe
    Lee, Kyung-A
    Jeong, Joon
    JOURNAL OF BREAST CANCER, 2014, 17 (01) : 1 - 7
  • [48] Expression of tubulin, p53, Ki67, receptors for estrogen, and progesterone in endometrial cancer
    Zhu, C.
    Luo, J.
    Shi, H.
    Xie, X.
    Ding, Z.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2009, 30 (05) : 514 - 517
  • [49] The p53 Codon 72 Exon 4 BstUI Polymorphism and Endometrial Cancer in Caucasian Women
    Zubor, Pavol
    Stanclova, Andrea
    Kajo, Karol
    Hatok, Jozef
    Klobusiakova, Dasa
    Visnovsky, Jozef
    Danko, Jan
    ONCOLOGY, 2009, 76 (03) : 173 - 183
  • [50] Racial disparity in overexpression of the p53 tumor suppressor gene in stage I endometrial cancer
    Clifford, SL
    Kaminetsky, CP
    Cirisano, FD
    Dodge, R
    Soper, JT
    ClarkePearson, DL
    Berchuck, A
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1997, 176 (06) : S229 - S232